Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma; and which is in Phase Ib monotherapy trial in multiple tumor types for the treatment of refractory solid tumors, as well as IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. The company is also developing IDRA-008 apolipoprotein C-III gene target for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; nucleic acid chemistry compound for renal target; and IMO-9200 for treating non-malignant gastrointestinal disorders. In addition, it is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GlaxoSmithKline Intellectual Property Development Limited to license, research, develop, and commercialize pharmaceutical compounds from its nucleic acid chemistry technology for the treatment of selected targets in renal disease; Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IDRA
CUSIPN/A
Phone484-348-1600
Debt
Debt-to-Equity RatioN/A
Current Ratio6.96
Quick Ratio6.96
Price-To-Earnings
Trailing P/E Ratio-2.48
Forward P/E Ratio-3.22
P/E GrowthN/A
Sales & Book Value
Annual Sales$900,000.00
Price / Sales251.17
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)($3.36)
Net Income$-65,980,000.00
Net Margins-8,686.36%
Return on Equity-74.17%
Return on Assets-65.51%
Miscellaneous
Employees62
Outstanding Shares27,170,000
Market Cap$217.12 million
Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions
What is Idera Pharmaceuticals' stock symbol?
Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."
When did Idera Pharmaceuticals' stock split? How did Idera Pharmaceuticals' stock split work?
Idera Pharmaceuticals's stock reverse split on the morning of Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 27th 2018. An investor that had 100 shares of Idera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.
How were Idera Pharmaceuticals' earnings last quarter?
Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced its earnings results on Thursday, August, 2nd. The biotechnology company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.23. The biotechnology company earned $0.16 million during the quarter, compared to the consensus estimate of $0.18 million. Idera Pharmaceuticals had a negative return on equity of 74.17% and a negative net margin of 8,686.36%. View Idera Pharmaceuticals' Earnings History.
When is Idera Pharmaceuticals' next earnings date?
What price target have analysts set for IDRA?
5 brokers have issued 12-month price objectives for Idera Pharmaceuticals' shares. Their predictions range from $15.00 to $32.00. On average, they expect Idera Pharmaceuticals' share price to reach $24.20 in the next twelve months. This suggests a possible upside of 190.9% from the stock's current price. View Analyst Price Targets for Idera Pharmaceuticals.
What is the consensus analysts' recommendation for Idera Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Idera Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Idera Pharmaceuticals.
What are Wall Street analysts saying about Idera Pharmaceuticals stock?
Here are some recent quotes from research analysts about Idera Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. " (8/9/2018)
- 2. HC Wainwright analysts commented, "We are maintaining our Buy rating of IDRA and adjust our 12-month price target to $18.00 from $4.00. We derive our price target based on a risk-adjusted net present value analysis of projected tilsotolimod revenues through 2027 assuming a 12% discount rate and 3% terminal growth rate." (8/6/2018)
Who are some of Idera Pharmaceuticals' key competitors?
Some companies that are related to Idera Pharmaceuticals include Acorda Therapeutics (ACOR), BAVARIAN NORDIC/S (BVNRY), Heska (HSKA), BioCryst Pharmaceuticals (BCRX), Nightstar Therapeutics (NITE), Fate Therapeutics (FATE), Scholar Rock (SRRK), Voyager Therapeutics (VYGR), Replimune Group (REPL), Mesoblast (MESO), Vericel (VCEL), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), NanoString Technologies (NSTG) and CASI Pharmaceuticals (CASI).
Who are Idera Pharmaceuticals' key executives?
Idera Pharmaceuticals' management team includes the folowing people:
- Mr. Vincent J. Milano, Pres, CEO & Director (Age 54)
- Mr. Louis J. Arcudi III, MBA, Sr. VP of Operations, CFO, Treasurer & Assistant Sec. (Age 57)
- Dr. Jonathan Yingling, Sr. VP of Early Devel. & Chief Scientific Officer (Age 49)
- Mr. Robert Clayton Fletcher, Sr. VP of Bus. Devel. & Strategic Planning (Age 55)
- Dr. Joanna C. Horobin, Sr. VP & Chief Medical Officer (Age 63)
Has Idera Pharmaceuticals been receiving favorable news coverage?
Media stories about IDRA stock have trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Idera Pharmaceuticals earned a news impact score of 0.18 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Idera Pharmaceuticals.
Who are Idera Pharmaceuticals' major shareholders?
Idera Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (142.27%), BlackRock Inc. (36.97%), FMR LLC (14.43%), Millennium Management LLC (9.35%), Northern Trust Corp (6.54%) and Bank of New York Mellon Corp (1.71%). Company insiders that own Idera Pharmaceuticals stock include Bros Advisors Lp Baker, Invest Corp Pillar, James A Geraghty, Julian Baker and Maxine Gowen. View Institutional Ownership Trends for Idera Pharmaceuticals.
Which institutional investors are selling Idera Pharmaceuticals stock?
Which institutional investors are buying Idera Pharmaceuticals stock?
IDRA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Alps Advisors Inc., GSA Capital Partners LLP, Northern Trust Corp, Berson & Corrado Investment Advisors LLC, California Public Employees Retirement System, Rhumbline Advisers and Baker BROS. Advisors LP. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, James A Geraghty, Julian Baker and Maxine Gowen. View Insider Buying and Selling for Idera Pharmaceuticals.
How do I buy shares of Idera Pharmaceuticals?
Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Idera Pharmaceuticals' stock price today?
One share of IDRA stock can currently be purchased for approximately $8.32.
How big of a company is Idera Pharmaceuticals?
Idera Pharmaceuticals has a market capitalization of $217.12 million and generates $900,000.00 in revenue each year. The biotechnology company earns $-65,980,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis. Idera Pharmaceuticals employs 62 workers across the globe.
How can I contact Idera Pharmaceuticals?
Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The biotechnology company can be reached via phone at 484-348-1600 or via email at [email protected]
MarketBeat Community Rating for Idera Pharmaceuticals (NASDAQ IDRA)
MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote "Outperform" if you believe IDRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
